Stay updated with breaking news from Arch Pathol Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023
NASHVILLE and PHILADELPHIA (PRWEB) March 01, 2023 -- Proscia®, a leading provider of digital and computational pathology solutions, today announced
Approval based on DESTINY-Breast04 results where Daiichi Sankyo and AstraZeneca's ENHERTU reduced the risk of disease progression or death by 50% and increased median overall survival by more than
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed ...
/PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced an agreement with AstraZeneca and Daiichi Sankyo,...